Skip to content

Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer

Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05365997
Acronym
BE-EPiC
Enrollment
266
Registered
2022-05-09
Start date
2022-05-23
Completion date
2023-08-08
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer, Palliative Care, Behavioral Economics

Brief summary

Patients with cancer often undergo costly therapy and acute care utilization that is discordant with their wishes, particularly at the end of life. Despite early palliative care consultations being a National Comprehensive Cancer Network (NCCN) guideline-concordant practice in advanced cancer, palliative care referral rates for stage IV patients are low. In this project, the investigators will evaluate a health system initiative that uses behavioral nudges to prompt palliative care referrals among outpatients with advanced cancer in terms of successful palliative care referrals and downstream quality of life outcomes. In partnership with the health system, this will be conducted as a 2-arm pragmatic cluster randomized trial.

Detailed description

Patients with advanced cancer have poor quality of life and life expectancy. Palliative care is a medical specialty focusing on providing relief from the symptoms and stress of serious illnesses such as cancer. While palliative care referrals often occur in the inpatient setting for acutely ill individuals, early outpatient specialty palliative care concurrent with cancer-directed treatment improves quality of life and survival, is an evidence-based practice, and is endorsed by national guidelines. Palliative care can be provided in the ambulatory, telemedicine, or home-based settings. However, nearly half of patients with advanced cancer do not receive palliative care prior to dying. Lack of standardized referral criteria and screening methods for palliative care contributes to underutilization. There is a high need for strategies to increase use of palliative care in oncology. Clinicians underutilize palliative care, initiating referrals a median of 2 months before death. This status quo bias, which predisposes clinicians to continue current practice even if not the optimal option, may lead to delayed or missed palliative care referrals. Additionally, optimism bias, the cognitive bias that causes clinicians to believe that their own patients are at lesser risk of negative outcomes, may cause clinicians to underestimate a patient's mortality risk or symptom burden, thus delaying palliative care referral. Finally, overconfidence bias, the propensity to overestimate one's desired behaviors when it is not objectively reasonable, may lead clinicians to incorrectly believe they are initiating more palliative care referrals than their peers. Overcoming suboptimal clinician decision-making biases are key to increasing palliative care referrals. Principles from behavioral economics can inform nudges that change how clinicians receive information and make choices such as palliative care referral. Default, opt-out nudges that make the optimal choice the path of least resistance can mitigate clinicians' status quo bias. Reframing clinicians' prognoses by providing data-driven life expectancy assessments may combat optimism bias. Early palliative care intervention can improve quality of life for patients with advanced cancer. Outpatient palliative care is available at 98% of National Cancer Institute (NCI)-designated cancer centers and 63% of non-NCI centers. Early outpatient palliative care concurrent with cancer-directed treatment improves quality of life, reduces symptom burden, and decreases rates of aggressive end of life care. Nevertheless, only a minority of patients who qualify for palliative care receive it. The primary objective of the study is to evaluate the impact of sending behavioral nudges to clinicians, as compared to usual practice, on completion of palliative care referrals among patients with advanced cancer. Our secondary objectives are to identify the impact of prompted palliative care referrals on quality of life, acute care utilization, and end-of-life utilization. This is a 2-arm pragmatic randomized trial among approximately 250 outpatients with advanced cancer to assess response to behavioral nudges to refer to palliative care. The setting will be outpatient oncology at the Ann B. Barshinger Cancer Institute at Lancaster General Health. Eligible clinicians will be randomized in clusters by overlapping clinical team (pod) to receive default electronic medical record-based prompts for palliative care referral among advanced cancer patients (Arm 1) vs no intervention/usual practice (Arm 2). These nudges have been shown to positively influence clinician behavior and are often used to drive value-based oncology care; however, they have never been studied in the context of palliative care referral. The primary outcome is completion of a palliative care referral within 12 weeks of enrollment.

Interventions

OTHERDefault Nudge

For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.

Sponsors

Abramson Cancer Center at Penn Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Investigator)

Intervention model description

Each clinician pod will be randomized in a 1:1 fashion to either intervention or usual care.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have a functional telephone number * Receive ongoing care from hematology/oncology services within the Ann B. Barshinger Cancer Institute (ABBCI) at Lancaster General Health.

Exclusion criteria

* Patients appearing for a new patient visit * Patients who have previously received palliative care * Patients who are enrolled in an ongoing clinical trial of a therapeutic agent * Patients who receive primary oncologic care within another institution

Design outcomes

Primary

MeasureTime frameDescription
Completion of Palliative Care VisitWithin 12 weeks of the Index VisitBinary outcome (yes/no) measured at the patient level among eligible patients based on the date of documented palliative care encounter

Countries

United States

Participant flow

Participants by arm

ArmCount
Control
Usual Care
136
Intervention
Nudge group
130
Total266

Baseline characteristics

CharacteristicControlInterventionTotal
Advanced Solid Malignancy131 Participants128 Participants259 Participants
Age, Continuous66.9 years
STANDARD_DEVIATION 13
66 years
STANDARD_DEVIATION 12.7
66.5 years
STANDARD_DEVIATION 12.9
Brain Metastasis11 Participants14 Participants25 Participants
Diagnosis
Brain
1 Participants0 Participants1 Participants
Diagnosis
Breast
25 Participants25 Participants50 Participants
Diagnosis
CNS
0 Participants1 Participants1 Participants
Diagnosis
Colon/rectal/anal
30 Participants16 Participants46 Participants
Diagnosis
GI
17 Participants7 Participants24 Participants
Diagnosis
GU
4 Participants12 Participants16 Participants
Diagnosis
GYN
1 Participants25 Participants26 Participants
Diagnosis
Head and neck
3 Participants12 Participants15 Participants
Diagnosis
Liver
1 Participants0 Participants1 Participants
Diagnosis
Lung
33 Participants12 Participants45 Participants
Diagnosis
Melanoma
5 Participants2 Participants7 Participants
Diagnosis
Other
12 Participants15 Participants27 Participants
Diagnosis
Pancreatic
4 Participants2 Participants6 Participants
Diagnosis
Thoracic
0 Participants1 Participants1 Participants
ECOG > 21 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Ethnicity
Hispanic
3 Participants3 Participants6 Participants
Race/Ethnicity, Customized
Ethnicity
non-Hispanic
133 Participants127 Participants260 Participants
Race/Ethnicity, Customized
Race
Asian
3 Participants0 Participants3 Participants
Race/Ethnicity, Customized
Race
Black or African American
3 Participants4 Participants7 Participants
Race/Ethnicity, Customized
Race
Mixed
0 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Race
Unknown/not reported
1 Participants2 Participants3 Participants
Race/Ethnicity, Customized
Race
White
129 Participants123 Participants252 Participants
Sex: Female, Male
Female
74 Participants73 Participants147 Participants
Sex: Female, Male
Male
62 Participants57 Participants119 Participants
Uncontrolled symptoms28 Participants26 Participants54 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
23 / 13615 / 130
other
Total, other adverse events
0 / 1360 / 130
serious
Total, serious adverse events
0 / 1360 / 130

Outcome results

Primary

Completion of Palliative Care Visit

Binary outcome (yes/no) measured at the patient level among eligible patients based on the date of documented palliative care encounter

Time frame: Within 12 weeks of the Index Visit

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
ControlCompletion of Palliative Care Visit11 Participants
InterventionCompletion of Palliative Care Visit19 Participants

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026